TITLE

Erectile dysfunction

AUTHOR(S)
Katz, Alan; Katz, Anne
PUB. DATE
March 2010
SOURCE
CMAJ: Canadian Medical Association Journal;3/9/2010, Vol. 182 Issue 4, p381
SOURCE TYPE
Academic Journal
DOC. TYPE
Question & Answer
ABSTRACT
The article presents questions & answers related to erectile dysfunction including whether there is evidence of a cardiovascular disease, whether there are potencially reversible causes, and what laboratory testing are required.
ACCESSION #
48490520

 

Related Articles

  • Counterpoint: The Oral Glucose Tolerance Test Is Superfluous. Davidson, Mayer B. // Diabetes Care;Oct2002, Vol. 25 Issue 10, p1883 

    Argues against the use of oral glucose tolerance tests in clinical medicine. Suggestion that the test does not provide information that cannot be obtained by other means; Use of the test to diagnose impaired glucose tolerance or diabetes; Risk factors for cardiovascular disease, including...

  • Point: A Glucose Tolerance Test Is Important for Clinical Practice. Tuomilehto, Jaakko // Diabetes Care;Oct2002, Vol. 25 Issue 10, p1880 

    Focuses on the importance of glucose tolerance tests in clinical practice. Report that asymptomatic diabetes increases the risk of cardiovascular disease and all-cause mortality; Determination of hyperglycemia; Discussion of screening for blood glucose among high risk patients; Problems with...

  • Association between erectile dysfunction and cardiovascular risk in individuals with type-2 diabetes without overt cardiovascular disease. Meena, Babu Lal; Kochar, Dhanpat Kumar; Agarwal, Tulsi Das; Choudhary, Raghvendra; Kochar, Abhishek // International Journal of Diabetes in Developing Countries;Oct-Dec2009, Vol. 29 Issue 4, p150 

    Background: Erectile dysfunction in type-2 diabetes may be an independent marker for coronary artery disease. Present study was undertaken to investigate whether type-2 diabetic patients with erectile dysfunction without having overt cardiovascular disease had increased cardiovascular risk. Aim:...

  • Cholesterol screening on the spot.  // GP: General Practitioner;8/11/2003, p44 

    As the reality of hitting contract targets grows closer, Dr. Bryan Palmer tests a device that will help one achieve more of them. The Accutrend GC is billed as a fast, accurate, on-the-spot health screening device designed to help identify and monitor patients with high blood cholesterol and...

  • Point: Intensive Glycemic Control and Mortality in ACCORD--A Chance Finding? LACHIN, JOHN M. // Diabetes Care;Dec2010, Vol. 33 Issue 12, p2719 

    The author comments on the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. He mentions that the study was designed to determine whether intensive blood glucose management aimed at a normal A1C (<6%) versus standard therapy aimed at an A1C of 7-8% would lower cardiovascular...

  • Prevalence of 'Borderline' Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy: Results of the BORDERLINE Study. Tocci, Giuliano; Ferrucci, Andrea; Passerini, Jasmine; Averna, Maurizio; Bellotti, Paolo; Bruno, Graziella; Cosentino, Francesco; Crepaldi, Gaetano; Giannattasio, Cristina; Modena, Maria Grazia; Nati, Giulio; Tiengo, Antonio; Trimarco, Bruno; Vanuzzo, Diego; Volpe, Massimo // High Blood Pressure & Cardiovascular Prevention;May2011, Vol. 18 Issue 2, p43 

    Introduction: The prevalence of patients with 'borderline' levels of cardiovascular risk factors has been rarely investigated, being often reported in studies evaluating abnormal values of these parameters. The BORDERLINE study represents a pilot experience to primarily identify the prevalence...

  • Impotence: treatment by autoinjection of vasoactive drugs. Williams, Gordon; Mulcahy, M.J.; Kiely, E.A. // British Medical Journal (Clinical Research Edition);9/5/1987, Vol. 295 Issue 6598, p595 

    Examines the treatment of men with organic impotence by autoinjection of vasoactive drugs. Treatment of men having venous leaks by surgery; Availability of penile revascularization procedures; Measurement of blood glucose and plasma lipid concentrations.

  • Effects of Acarbose on Proinsulin and Insulin Secretion and their Potential Significance for the Intermediary Metabolism and Cardiovascular System. Rosaka, Christoph; Mertes, Gabriele // Current Diabetes Reviews;2009, Vol. 5 Issue 3, p157 

    The alpha-glucosidase inhibitor acarbose is administered to control blood glucose levels in type 2 diabetic patients and, in several countries, in those with impaired glucose tolerance. The efficacy and safety of the drug has been well established in these patient populations. Acarbose shows no...

  • Firm glucose control may diminish CV benefit in patients with diabetes, comorbidities.  // Endocrine Today;Jan2010, Vol. 8 Issue 1, p18 

    The article focuses on a study which discovered the failure of strict blood glucose control to reduce the risk of cardiovascular events or mortality in patients with type 2 diabetes and comorbidities.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics